Evidence map›Paper›PMID 37337059›Full record

ArticleCardiovascular and interventional radiology2023

Prospective Series of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with 30-60 μm Microspheres Loaded with Irinotecan.

K Malagari, Th Kiakidis, H Moschouris, A Charokopakis, C Vergadis, N Alevisopoulos, V Kartsouni, Ir Panagiotou, O Pellerin, G Glantzounis and 6 more

Registry-linked trialAbstract readClinical Study
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04866290 (Prospective Registry of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver With HepaSphere™ Microspheres Loaded With Irinotecan), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04866290 completednot on this map

Prospective Registry of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver With HepaSphere™ Microspheres Loaded With Irinotecan

TypeobservationalSponsorMerit Medical Systems, Inc.Ran2016 to 2021Enrolled105ConditionsMetastatic Colorectal CancerArmsHepaSphere Microspheres
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

K MalagariDepartment of Radiology, Medical School, National and Kapodistrian University of Athens, 19 Monis Kyccou, 15 669 Papagou, Athens, Greece. kmalag@otenet.gr.ORCID http://orcid.org/0000-0002-1391-0965
Th KiakidisDepartment of Radiology, Medical School, National and Kapodistrian University of Athens, 19 Monis Kyccou, 15 669 Papagou, Athens, Greece.
H MoschourisInterventional Radiology Department, Tzanion General Hospital, Piraeus, Athens, Greece.
A CharokopakisDepartment of Radiology, Medical School, National and Kapodistrian University of Athens, 19 Monis Kyccou, 15 669 Papagou, Athens, Greece.
C VergadisLaikon General Hospital, Athens, Greece.
N AlevisopoulosEvangelismos Hospital, Athens, Greece.
V KartsouniDepartment of Interventional Radiology, Agios Savvas Anticancer Hospital, Athens, Greece.
Ir PanagiotouDepartment of Internal Medicine, Agios Savvas Anticancer Hospital, Αthens, Greece.
O PellerinInterventional Radiology, Université de Paris-Citè, PARCC, INSERM, 75006, Service de Radiologie Interventionnelle Assistance Publique - Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
G GlantzounisIoannina University Hospital, Ioannina, Greece.
D K FilippiadisDepartment of Radiology, Medical School, National and Kapodistrian University of Athens, 19 Monis Kyccou, 15 669 Papagou, Athens, Greece.
E EmmanouilDepartment of Radiology, Amalia Fleming Hospital, Athens, Greece.
N TsavarisLaikon Hospital, Athens, Greece.
G PsarrosASTAT-Statistics in Clinical Research, 166 75, Athens, Greece.
E DelichaASTAT-Statistics in Clinical Research, 166 75, Athens, Greece.
N KelekisDepartment of Radiology, Medical School, National and Kapodistrian University of Athens, 19 Monis Kyccou, 15 669 Papagou, Athens, Greece.
National and Kapodistrian University of Athens · GRLaiko General Hospital of Athens · GRSt Savas Hospital · GREvangelismos Hospital · GRInserm · FRSimanogleio-Amalia Fleming General Hospital · GRTzaneion General Hospital · GRUniversity Hospital of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe safety and clinical outcomes among patients with metastatic colorectal cancer (mCRC) to the liver treated with transarterial chemoembolization with HepaSphere™ Microspheres 30-60 μm loaded with irinotecan (ΙRI-HEP-TACE). MATERIAL AND

methodsIn this prospective study (NCT04866290), 100 adults with confirmed mCRC to the liver who were ineligible for resection were enrolled and followed up to 24 months or death. Study outcomes among Salvage (patients not tolerating more cycles of chemotherapy) and Non-salvage patients included overall survival (OS), progression-free survival (PFS), objective response (OR), objective response rate (ORR), best tumor response (BTR), adverse events (AEs), and pharmacokinetics of irinotecan and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN38).

resultsThe median age was 66 years (range: 31-89). Median OS was 15.08 months (95% confidence interval [CI]: 12.33-17.25). PFS was 8.52 months (95% CI: 6.0-9.0; p < 0.001). ORR was 42.2% (95% CI: 31.57-53.50) and 35.9% (95% CI: 25.57-47.62) based on modified RECIST (Response Evaluation Criteria in Solid Tumors) and RECIST 1.1 criteria. BTR was not significantly different between mRECIST and RECIST (p = 0.745). The Non-salvage group had a statistically significant difference in median OS relative to the Salvage group (15.3 vs. 3 months; p < 0.001). Pharmacokinetic analyses demonstrated no correlation of OS with plasma concentration of irinotecan and SN38 (all p > 0.05). Most AEs were Grade 2 (257/279), the most common AE was right upper abdominal pain (180/279). One major AE (tumor rupture) was reported.

conclusionIRI-HEP-TACE is an alternative treatment for patients with Non-salvage mCRC to the liver.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticColonic NeoplasmsColorectal NeoplasmsLiver NeoplasmsRectal NeoplasmsAdultAgedAged, 80 and overHumansIrinotecanMicrospheresMiddle AgedProspective StudiesIrinotecanDrug-eluting microspheresHepaSphere™ microspheres 30–60 μmIrinotecanLiver metastatic colorectal cancer (mCRC)

Identifiers

PMID37337059
OpenAlexW4381188116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.